Search Results

for Drug Discovery DMS: Linking Protein Structure To Function AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma attended the Drug Discovery Ecosystem Summit Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million Tectonic Therapeutic Announces

week:  nanomedicines targeting PAR2 for sustained analgesia; Emerging Voices in GPCR Biology; Domain Therapeutics Scientist—In-vitro Pharm; Postdoc roles. Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about

Antibodies, Bias, and the Expanding Modality Landscape Antibody therapeutics are now entering spaces Advance: What Real Teams Do How do large pharma teams decide whether to advance or pause a GPCR program What happens inside Big Pharma when programs are paused or advanced.

this week:  Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma When “inhibition” becomes activation—and how that insight fuels next-gen therapeutic design. Kenakin Trusted insights across biotech, pharma, and academia 💎 $2,999/year — one conference cost =

GPCR Binders, Drugs, and more Advances in structure-based drug design: The potential for precision therapeutics Mechanisms of G Protein-Coupled Receptors through Structural Biology Industry News INV-347 by Inversago Pharma Septerna to Participate in Upcoming Investor and Industry Conferences Sosei and IPJ to become Nxera Pharma Opportunities in Pharmacology and Drug Discovery NEW March 13 - 15 | Biologics 2024 March 13 - 15 | 9th German Pharm-Tox

Whether supporting CROs, academic labs, or pharma teams, Celtarys engages deeply with collaborators to

GPCRs in Neuroscience G protein coupled receptors as targets for transformative neuropsychiatric therapeutics GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment Clinical and Preclinical Development The pathway of opioid drugs into cellular structures Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics attended GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Exscientia Business Update for Second Quarter and First Half of 2023 Novo Nordisk to acquire Inversago Pharma Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics

News from December 2nd to 8th, 2024 Industry News 2024 Fellows and Honorary Fellows announced Nxera Pharma to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Pharmacology GPCR Jobs GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

That choice determines whether you risk over- or under-dosing, miss safety windows, or miss therapeutic More nuanced control, fewer off-target liabilities, and novel therapeutic windows. Correctly distinguishing these mechanisms helps refine therapeutic index calculations, prioritize safer topic suggestions 🆕 Weekly new releases to stay ahead of the science 🧠 Content built for biotech, pharma

and triterpenes isolated from Cryptostegia grandiflora against Candida auris FKBP12 Development and therapeutic Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner Monlunabant by Inversago Pharma Likelihood of Approval Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio Addex Pharma

November 7th : Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th : Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. with Generative AI Nxera Pharma receives approval of insomnia drug in Japan Lilly and Novo Spend Billions with SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism Confo Therapeutics a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety OMass Therapeutics

Did you know that each month we collect the most recent #GPCR publications and the newest Biotech/Pharma

Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology GPCR Symposium on 'GPCRs as Therapeutic Modalities'. and oligomerization Molecular Insights into GPCR Mechanisms for Drugs of Abuse Industry News 'GPCR Therapeutics Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO Novo Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic Antibodies Using AI ONCORNET2.0

Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Industry News MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 Certa Therapeutics proteins for biology and health research Innovate UK announced the winners of its Transforming Cancer Therapeutics 𝗦𝘂𝗺𝗺𝗮𝗿𝘆 𝗼𝗳 𝘁𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗼𝗳 𝗔𝗘𝗙𝟬𝟭𝟭𝟳 𝗣𝗵𝗮𝘀𝗲 𝟮𝗯 𝗶𝗻 𝗖𝗨𝗗 Nxera Pharma

Bryan Roth and Brian Krumm for their study on Molecular glues as potential GPCR therapeutics Drs. breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects GPR56: A potential therapeutic via site-selective activation of mTOR GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics hormone recognition and distinctive Gq protein coupling by the kisspeptin receptor Industry News Nxera Pharma

Jonasson, CFO & CBO at Absci Octant: A Next Generation Approach to Genetic Disease Antiverse, Nxera Pharma How Structural Biology Informs the Development of Drugs Targeting G Protein-Coupled Receptors ARTICA THERAPEUTICS to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox GPCR Jobs NEW GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

GPCR Symposium about 'GPCRs as Therapeutic Modalities' rocked it! Relocation AI can help to speed up drug discovery — but only if we give it the right data Inversago Pharma recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Confo Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

Industry News Domain Therapeutics was one of the 4 Biotech Trophy nominees at 2023 HealthTech awards. Function Therapeutics has been awarded a Phase 1 SBIR grant from NSF. Function Therapeutics has a new website. Call for GPCR Papers GPCRs: Signal Transduction. Webinar - Antiverse: Engineering the Future of Drug Discovery (March 30, 2023) NEW Molecular Dynamics in Pharma

From omics to epigenetics The impact of nanobodies on GPCR structural biology and their potential as therapeutic agents Industry News Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter complexes with MolBoolean Screening GPR75 Modulators Using Medium-Throughput Reporter Gene Assay GPCR Therapeutics

tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics Treatment Of Congenital Adrenal Hyperplasia (CAH) And Acth-Dependent Cushing’s Syndrome (ADCS) Nxera Pharma

News UNC School of Medicine to Receive $3-Million Award from ARPA-H’s Sprint for Women’s Health Nxera Pharma 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic

Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Let’s dive into the   Classified GPCR News from September 16th to 22nd, 2024 Industry News Inversago Pharma INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion Therapeutics ) – BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK

Career opportunities:  Exclusive pharma and academic listings you won’t find on job boards—curated for Leverage this model to stay ahead of therapeutic complexity.

GPCRs in Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Deorphanization of G Protein Coupled Receptors (GPCRs): a historical perspective Industry News Addex Therapeutics at the 19th Biopharma Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024 Domain Therapeutics MacDonald as Chief Executive Officer Nxera Pharma Announces Exclusive Supply and Distribution Agreement

Richard is the architect behind nearly all of Exscientia's partnerships and collaborations across pharma

Tethered Ligands that Target the µ-Opioid Receptor Design and Synthesis of Novel GPR139 Agonists with Therapeutic drugs hunt Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma

It’s about revealing therapeutic liabilities before  they derail development. constitutive activity play in uncovering inverse agonists , and how can you exploit this phenomenon for novel therapeutic Kenakin Content trusted by biotech, pharma & academia 💎 $2999/year — one conference cost = a full

Insights into GPCR Function Time-resolved cryo-EM of G-protein activation by a GPCR Industry News Domain Therapeutics to advance novel anti-CCR8 antibody  for cancer immunotherapy Novo Holdings Portfolio Company Amolyt Pharma Protein Structures Newly discovered adhesion GPCR mayo controls midgut development in Drosophila Karuna Therapeutics

cAMP-PKA-CREB signaling pathway based on network pharmacology and bioinformatics analysis Unveiling the therapeutic News Monash University pharmaceutical scientists honoured in NHMRC Research Excellence Awards Domain Therapeutics Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Confo Therapeutics Development In Endocrine And Metabolic Diseases How biotech companies are using AI to design drugs GPCR Therapeutics